TNFα News and Research

RSS

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

11 May 2012

New biomarkers can predict risk of kidney failure in patients with diabetes

Scientists at Joslin Diabetes Center have identified two novel markers that, when elevated in the blood stream, can predict accurately the risk of renal (kidney) failure in patients with Type 1 and Type 2 diabetes.

20 Jan 2012

Scientists discover mechanism by which TNFα stimulates tumor formation

An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.

23 Dec 2011

Study: Omega-3 supplements can decrease inflammation, anxiety

A recent study gauging the impact of consuming more fish oil showed a marked reduction both in inflammation and, surprisingly, in anxiety among a cohort of healthy young people.

10 Nov 2011

Colonoscopic FMT effective in treating IBD, C.difficile-associated diarrhea

Growing evidence for the effectiveness of fecal microbiota transplants as a treatment for patients with recurrent bouts of Clostridium difficile (C.difficile) associated diarrhea is presented in three studies -- including a long-term follow-up of colonoscopic fecal microbiota transplant (FMT) for recurrent C. difficile Infection that included 77 patients from five different states-- unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Short-term glucocorticoid treatment may prevent osteoarthritis after joint injury

Joint injury can result in irreversible damage of cartilage which, despite treatment and surgery, often eventually leads to osteoarthritis (OA) in later life. New research published in BioMed Central's open access journal Arthritis Research & Therapy demonstrates that short term treatment of damaged cartilage with glucocorticoids can reduce long term degenerative changes and may provide hope for prevention of OA after injury.

2 Sep 2011

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Many of the world's preeminent gastroenterologists will gather for the American College of Gastroenterology's (ACG) 75th Annual Scientific Meeting at the Henry B. Gonzalez Convention Center in San Antonio, Texas starting Monday October 18, 2010, to review the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.

19 Oct 2010

Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis

Estimates of the prevalence of liver disease suggest that one‐third of the United States population has non‐alcoholic fatty liver disease (NAFLD). NAFLD is now the most common cause for elevated liver function tests in the United States, a trend related to the obesity epidemic in this country. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to cirrhosis and all its complications.

19 Oct 2010

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).

8 Dec 2009

Mayo study reveals infliximab reduces the need for colectomy

A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology.

1 Oct 2009

Signaling molecules have different effects on key inhibitory protein

Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical Investigation.

22 Sep 2009

Alcoholism may be dependent on IL-1 polymorphisms: Study

Cytokines are small proteins secreted by cells that serve as molecular messengers between cells. Pro-inflammatory cytokines - which function in the immune system - may be involved in alcohol dependence (AD). A study of three polymorphisms of the interleukin-1 gene complex (IL-1) and one of the tumor necrosis factor-alpha (TNFα) has found that IL-1 may directly contribute to AD among Spanish Caucasian males.

21 Sep 2009

A new slow-release hydrogen sulfide donating molecule may hold the key to the development of new anti-inflammatory drugs

Researchers from the Peninsula Medical School in Exeter have synthesized a new molecule which releases hydrogen sulfide (H2S) - the gas that gives rotten eggs their characteristic smell and which has recently been found to be produced naturally in the body - and discovered that it could in time lead to a range of new, safer and effective anti-inflammatory drugs for human use.

20 May 2009